
|Articles|September 13, 2017
Should the Availability of High-Dose Opioids Be Reduced?
In this video from PainWeek 2017, Hal Blatman, MD, medical director of Blatman Health and Wellness Center, discusses whether the FDA should reduce the availability of high-dose opioids in response to the growing opioid abuse epidemic.
Advertisement
In this video from PainWeek 2017, Hal Blatman, MD, medical director of Blatman Health and Wellness Center, discusses whether the FDA should reduce the availability of high-dose opioids in response to the growing opioid abuse epidemic.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Milestone Oral Therapy for Adults With Thalassemia Anemia
2
Reimagining Pharmacy: A Call to Action for Pharmacy Professionals
3
FDA Approves Nufymco, Interchangeable Ranibizumab Biosimilar, for Retinal Diseases
4
Lowering Blood Glucose in Prediabetes May Prevent Heart Attacks and Heart Failure
5









































































































































































































